TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various conditions, has announced preliminary data from a feasibility study using Kernel Flow. The results indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. “Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during and after a psychedelic experience. Using the device, the study successfully measured the neuro-effect of ketamine over 11 days, confirming changes in functional connectivity that are consistent with current scientific research,” a recent article reads. “By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics,” said Cybin CEO Doug Drysdale. “Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space.”

To view the full article, visit https://ibn.fm/qeFT9

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork

Alex Pearon

Share
Published by
Alex Pearon

Recent Posts

TinyGemsBreaks – NextPlat Corp (NASDAQ: NXPL) Issues CEO Update, Reaffirms Commitment to Growth Following Leadership Transition

NextPlat (NASDAQ: NXPL, NXPLW) released a shareholder letter from Interim CEO expressing confidence in the…

1 day ago

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released…

4 days ago

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar 

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring…

7 days ago

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model 

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with…

7 days ago

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Acquires Nautical Ventures to Launch First Integrated Electric Boat Dealership in North America

Vision Marine Technologies (NASDAQ: VMAR), a leader in high-voltage electric marine propulsion, has acquired Nautical…

1 week ago

TinyGemsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Signs MOU to Advance Quantum Computing in South Korea

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced…

2 weeks ago